Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

2014; Wiley; Volume: 21; Issue: s1 Linguagem: Inglês

10.1111/jvh.12248

ISSN

1365-2893

Autores

Homie Razavi, Imam Waked, Christoph Sarrazin, Robert P. Myers, Ramazan İdilman, Filipe Calinas, W. Vogel, Maria Cássia Mendes Corrêa, Christophe Hézode, Pablo Lázaro, Ulus Salih Akarca, Soo Aleman, İsmail Balık, Thomas Berg, Florian Bihl, Marc Bilodeau, Antonio Javier Blasco, Carlos Eduardo Brandão‐Mello, Philip Bruggmann, Marı́a Buti, José Luís Calleja, Hugo Cheinquer, Peer Brehm Christensen, Mette Rye Clausen, Henrique Sergio Coelho, Matthew Cramp, G.J. Dore, W. Doss, Ann‐Sofi Duberg, Manal H. El‐Sayed, Gül Ergör, Gamal Esmat, Karolin Falconer, J Félix, Maria Lúcia Gomes Ferraz, Paulo Roberto Abrão Ferreira, Soňa Fraňková, Javier García‐Samaniego, Jan Gerstoft, José Gíria, Fernando Lopes Gonçales, E. Gower, Michael Gschwantler, Mário G. Pessôa, S. J. Hindman, Heribert Hofer, Petr Husa, Martin Kåberg, Kelly Kaita, Achim Kautz, Sabahattin Kaymakoğlu, Mel Krajden, Henrik Krarup, Wim Laleman, Daniel Lavanchy, Rui Tato Marinho, Paul Marotta, Stefan Mauss, Christophe Moreno, K. Murphy, Francesco Negro, Vratislav Němeček, Necati Örmecı, Anne Øvrehus, Julie Parkes, Ken Pasini, Kevork Peltekian, Alnoor Ramji, Nathalia Rodrigues dos Reis, S. Roberts, William Rosenberg, Françoise Roudot‐Thoraval, Stephen Ryder, Rui Sarmento‐Castro, David Semela, Morris Sherman, Gamal Shiha, William Sievert, Jan Šperl, Peter Stärkel, R.E. Stauber, A. Thompson, Petr Urbánek, Pierre Van Damme, Ingo van Thiel, Hans Van Vlierberghe, Dominique Vandijck, Heiner Wedemeyer, Nina Weis, Johannes Wiegand, A. Yosry, Amany Zekry, Markus Cornberg, Beat Müllhaupt, Chris Estes,

Tópico(s)

Hepatitis B Virus Studies

Resumo

Summary The disease burden of hepatitis C virus ( HCV ) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013–2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late‐stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV . Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver‐related deaths from increasing.

Referência(s)